Pacific Biosciences of California, Inc. (P09.F)

Compare

1.2204

-0.0314

(-2.51%)

As of 3:56:53 PM GMT+2. Market Open.

PacBio (PACB) and Hims & Hers Health (HIMS), 10x Genomics (TXG), Moderna (MRNA) Shares Are Soaring, What You Need To Know

A number of stocks jumped in the afternoon session after markets rallied sharply on news that President Trump announced a 90-day tariff pause. Reciprocal tariffs were also dropped to 10% for most countries, sparking renewed optimism amid ongoing trade talks. The major stock indices rose as investors, growing impatient of seemingly irrational tariff actions, welcomed the pause as a sign of a more measured path forward.

StockStory 21 hours ago

MRNA

TXG

PACB
PacBio Announces Preliminary First Quarter 2025 Revenue and Reiterates 2025 Revenue Guidance of $155 Million to $170 Million

Implements Plan to Reduce Annualized Operating Expense Run Rate by $45 Million to $50 Million Q1 2025 Earnings Conference Call Scheduled for May 8, 2025 MENLO PARK, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced preliminary, unaudited revenue for the quarter ended March 31, 2025. Preliminary First Quarter Results Preliminary Q1 2025Q1 2024Revenue$36.9 million$38.8 millionInstrument revenue$10.8 million$19.0 millionConsumable revenue$20.1 million$16.0 millionServ

GlobeNewswire yesterday

PACB
PacBio Grants Equity Incentive Award to New Employee

MENLO PARK, Calif., April 04, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced that the Compensation Committee of the Company’s Board of Directors granted a non-qualified stock option (the “Option”) covering 342,432 shares of PacBio common stock to the Company’s recently hired Chief Financial Officer, Jim Gibson, under the Pacific Biosciences 2020 Inducement Equity Incentive Plan (the “2020 Inducement Plan”)

GlobeNewswire 5 days ago

PACB
Jim Gibson to join PacBio as Chief Financial Officer

MENLO PARK, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced Jim Gibson will join and be appointed as the company’s new Chief Financial Officer, effective as of his start date, which is expected to be March 31, 2025. With over three decades of financial leadership experience at some of Silicon Valley’s most iconic and innovative companies, Mr. Gibson brings a deep track record of operation

GlobeNewswire 14 days ago

PACB
Pacific Biosciences of California (PACB) Advances While Market Declines: Some Information for Investors

Pacific Biosciences of California (PACB) reachead $1.26 at the closing of the latest trading day, reflecting a +0.8% change compared to its last close.

Zacks 20 days ago

PACB

^GSPC
Is Pacific Biosciences of California, Inc. (PACB) the Most Volatile Stock Under $3 For Day Trading?

We recently compiled a list of the 10 Most Volatile Stocks Under $3 For Day Trading. In this article, we are going to take a look at where Pacific Biosciences of California, Inc. (NASDAQ:PACB) stands against the pump and dump stocks. Day trading involves buying and selling stocks within a single trading day to capitalize […]

Insider Monkey 22 days ago

PACB
3 Reasons to Sell PACB and 1 Stock to Buy Instead

Shareholders of PacBio would probably like to forget the past six months even happened. The stock dropped 35.2% and now trades at $1.25. This was partly due to its softer quarterly results and might have investors contemplating their next move.

StockStory 23 days ago

PACB
Scientists Solve One of Genomics’ Biggest Challenges by Using HiFi Sequencing to Distinguish Highly Similar Paralogous Genes

MENLO PARK, Calif., March 17, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced a newly published study in Nature Communications unveiling a powerful new method for analyzing some of the most complex regions of the human genome. Led by researchers from PacBio, GeneDx, and a global consortium of genomics experts, the study utilizes Paraphase, an informatics tool that, when paired with HiFi long-read sequencing

GlobeNewswire 24 days ago

PACB
Q4 Rundown: PacBio (NASDAQ:PACB) Vs Other Life Sciences Tools & Services Stocks

Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at PacBio (NASDAQ:PACB) and its peers.

StockStory 24 days ago

TECH

RGEN

PACB
Pacific Biosciences of California (PACB) Increases Yet Falls Behind Market: What Investors Need to Know

In the closing of the recent trading day, Pacific Biosciences of California (PACB) stood at $1.22, denoting a +1.67% change from the preceding trading day.

Zacks 26 days ago

PACB
1 Healthcare Stock to Target This Week and 2 to Turn Down

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the industry’s returns - over the past six months, healthcare stocks have collectively shed 6.8%. This performance was disappointing since the S&P 500 climbed 1%.

StockStory 30 days ago

VTRS

BMRN

PACB
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Analysts Just Slashed This Year's Revenue Estimates By 14%

Market forces rained on the parade of Pacific Biosciences of California, Inc. ( NASDAQ:PACB ) shareholders today, when...

Simply Wall St. last month

PACB
PacBio to Participate in TD Cowen's 45th Annual Health Care Conference

MENLO PARK, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be presenting at TD Cowen's 45th Annual Health Care Conference on Tuesday, March 4, 2025, at 3:10 PM ET (12:10 PM PT) in Boston, MA. A live webcast of the event can be accessed at the company’s investors page at investor.pacificbiosciences.com. A replay of the webcast will be available for at least 30 days fol

GlobeNewswire last month

PACB
PacBio should return to growth over time, says Canaccord

Canaccord reiterates a Buy rating on PacBio (PACB) with a $3 price target following the company’s Q4 report. The firm says that although PacBio forecasts modest sales growth in 2025, it remains optimistic the company should be able to return to growth over time due to new products and improved execution. Canaccord points out management incorporated National Institutes of Health-related uncertainty into its 2025 guidance. The firm is optimistic PacBio’s is positioned “relatively well” in the curr

TipRanks last month

PACB
Pacific Biosciences of California Full Year 2024 Earnings: EPS Beats Expectations

Pacific Biosciences of California ( NASDAQ:PACB ) Full Year 2024 Results Key Financial Results Revenue: US$154.0m (down...

Simply Wall St. last month

PACB
PACB Stock Down Following In-Line Q4 Earnings, Revio Shipments Fall

Despite strong Service and other revenues, PacBio reports soft fourth-quarter 2024 results partly due to lower Revio system shipments.

Zacks last month

PACB

BSX

CAH
Pacific Biosciences of California Inc (PACB) Q4 2024 Earnings Call Highlights: Navigating ...

Despite a challenging macroeconomic environment, Pacific Biosciences of California Inc (PACB) reports strategic growth and cost management in Q4 2024.

GuruFocus.com last month

PACB
Compared to Estimates, Pacific Biosciences (PACB) Q4 Earnings: A Look at Key Metrics

While the top- and bottom-line numbers for Pacific Biosciences (PACB) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks last month

PACB
Pacific Biosciences of California (PACB) Reports Q4 Loss, Tops Revenue Estimates

Pacific Biosciences (PACB) delivered earnings and revenue surprises of 0% and 0.06%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks last month

PACB
PacBio (NASDAQ:PACB) Misses Q4 Sales Targets

Genomics company Pacific Biosciences of California (NASDAQ:PACB) missed Wall Street’s revenue expectations in Q4 CY2024, with sales falling 32.8% year on year to $39.22 million. Its non-GAAP loss of $0.20 per share was 15.5% below analysts’ consensus estimates.

StockStory last month

PACB

Performance Overview

Return	P09.F	S&P 500 (^GSPC)
YTD	-31.14%	-12.45%
1-Year	-61.81%	-0.22%
3-Year	-84.16%	+14.73%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Live

Pacific Biosciences of California, Inc. (P09.F)

PacBio (PACB) and Hims & Hers Health (HIMS), 10x Genomics (TXG), Moderna (MRNA) Shares Are Soaring, What You Need To Know

PacBio Announces Preliminary First Quarter 2025 Revenue and Reiterates 2025 Revenue Guidance of $155 Million to $170 Million

PacBio Grants Equity Incentive Award to New Employee

Jim Gibson to join PacBio as Chief Financial Officer

Pacific Biosciences of California (PACB) Advances While Market Declines: Some Information for Investors

Is Pacific Biosciences of California, Inc. (PACB) the Most Volatile Stock Under $3 For Day Trading?

3 Reasons to Sell PACB and 1 Stock to Buy Instead

Scientists Solve One of Genomics’ Biggest Challenges by Using HiFi Sequencing to Distinguish Highly Similar Paralogous Genes

Q4 Rundown: PacBio (NASDAQ:PACB) Vs Other Life Sciences Tools & Services Stocks

Pacific Biosciences of California (PACB) Increases Yet Falls Behind Market: What Investors Need to Know

1 Healthcare Stock to Target This Week and 2 to Turn Down

Pacific Biosciences of California, Inc. (NASDAQ:PACB) Analysts Just Slashed This Year's Revenue Estimates By 14%

PacBio to Participate in TD Cowen's 45th Annual Health Care Conference

PacBio should return to growth over time, says Canaccord

Pacific Biosciences of California Full Year 2024 Earnings: EPS Beats Expectations

PACB Stock Down Following In-Line Q4 Earnings, Revio Shipments Fall

Pacific Biosciences of California Inc (PACB) Q4 2024 Earnings Call Highlights: Navigating ...

Compared to Estimates, Pacific Biosciences (PACB) Q4 Earnings: A Look at Key Metrics

Pacific Biosciences of California (PACB) Reports Q4 Loss, Tops Revenue Estimates

PacBio (NASDAQ:PACB) Misses Q4 Sales Targets

Performance Overview